Target intelligence / Profile preview

C-type lectin domain family 12 member B (CLEC12B)

Target
CLEC12B
Molecular classification
C-type lectin receptor, Inhibitory receptor, Membrane protein
01

Overview

C-type lectin domain family 12 member B (CLEC12B) is a membrane-bound inhibitory receptor primarily expressed on myeloid cells. It is characterized by an extracellular C-type lectin-like domain and a cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM)[3][1]. Upon activation and phosphorylation, CLEC12B recruits SH2 domain-containing tyrosine phosphatases (SHP-1 and SHP-2), antagonizing activating signals within immune cells and contributing to immune homeostasis and protection of target tissues against natural killer cell-mediated lysis. CLEC12B is involved in processes such as regulation of melanocyte proliferation, inhibition of signal transduction, and modulation of immune cell activation during infection and inflammation. Genetic associations include cone-rod dystrophy 1[1][4][7]. No known direct drug interactions or biomarker uses have been identified for CLEC12B at this time.

Other names
Macrophage antigen HTestis secretory sperm-binding protein Li 205aUNQ5782/PRO16089CLEC12BC-type lectin domain family 12 member B, macrophage antigen hUNQ5782Macrophage antigen h
02

Mechanism of action

Recruitment of phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11) to its immunoreceptor tyrosine-based inhibition motif (ITIM), resulting in antagonism of activating immune cell signals and downregulation of specific cell activation pathways[1][3][7].

03

Biological functions

Immune response regulationSignal transduction inhibitionNatural killer cell inhibitionRegulation of melanocyte proliferationRegulation of cell cycle and differentiation (melanocytes)
04

Disease associations

InflammationInfectionImmune-related conditions(Potentially) CancerCone-rod dystrophy 1 (via genetic association)
05

Safety considerations

Potential risk of off-target immunosuppression if therapeutically modulated due to its role in downregulating immune cell activityImpact on protective immune functions (e.g., natural killer cell-mediated immunity)

Beyond the preview

Go deeper on C-type lectin domain family 12 member B (CLEC12B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-type lectin domain family 12 member B (CLEC12B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call